Unlocking Cures for Pediatric Cancer with Artificial Intelligence
Executive Order 14355, titled "Unlocking Cures for Pediatric Cancer with Artificial Intelligence," was signed by President Donald Trump on September 30, 2025, and published in the Federal Register on October 7, 2025 (Doc. No. 2025-19495, pages 48153–48155, Federal Register Vol. 90, No. 192).[1] The order directs the application of artificial intelligence to accelerate research, diagnosis, treatment, and prevention of childhood cancers, doubling the budget of the Childhood Cancer Data Initiative (CCDI) to $100 million annually and directing HHS, NIH, and OSTP to integrate AI into pediatric cancer research programs.
BackgroundEdit
Pediatric cancer is the leading cause of disease-related death among children aged 1–19 in the United States. Its incidence has increased by more than 40 percent since 1975. Despite representing a small fraction of overall cancer cases, pediatric cancers present unique biological challenges because they often differ fundamentally from adult cancers in their genetic drivers and response to treatment.[2]
The order was linked to the administration's broader Make America Healthy Again (MAHA) initiative. The MAHA Commission, established by Executive Order 14212 of February 13, 2025, had identified reversing pediatric cancer trends as a top priority. EO 14355 operationalized that commitment through an AI-specific research acceleration mandate.
President Trump had previously established the Childhood Cancer Data Initiative (CCDI) during his first term in 2019 to collect, generate, and analyze childhood cancer data across federal programs. EO 14355 directed that CCDI's budget double from $50 million to $100 million and be reoriented toward AI-enabled applications.[3]
Key ProvisionsEdit
Federal Agency DirectivesEdit
The order directed three primary federal entities to integrate AI into pediatric cancer research:
- Department of Health and Human Services (HHS) — Oversee and coordinate the AI-for-pediatric-cancer initiative across HHS components, including NIH and the National Cancer Institute
- National Institutes of Health (NIH) — Develop and fund AI research programs targeting pediatric cancer diagnosis, treatment, and prevention; expand data sharing infrastructure to support AI model training
- White House Office of Science and Technology Policy (OSTP) — Coordinate interagency efforts and ensure the initiative is integrated with broader federal AI policy[4]
MAHA Commission RoleEdit
The MAHA Commission was directed to develop innovative ways to utilize AI and other advanced technologies to unlock improved diagnoses, treatments, cures, and prevention strategies for pediatric cancer, and to report on progress against the EO's goals.
Childhood Cancer Data Initiative ExpansionEdit
The CCDI budget was increased from $50 million to $100 million annually. The initiative was directed to prioritize AI-ready data curation, ensuring the large-scale cancer genomics and clinical data the CCDI had been collecting would be structured and accessible for AI model training and validation.[5]
Research Focus AreasEdit
The order specified AI application priorities in pediatric oncology, including:
- AI-enhanced diagnostic imaging and pathology
- Genomic data analysis for treatment matching (precision medicine)
- Drug repurposing: identifying existing approved compounds with pediatric cancer efficacy
- Predictive modeling for treatment response and long-term survivorship outcomes
- AI-accelerated clinical trial matching and design[6]
ImplementationEdit
HHS moved quickly to implement the order, with an NIH news release announcing that HHS was doubling AI-backed childhood cancer research funding. The National Cancer Institute (NCI) and other NIH institutes began soliciting AI research grants specifically focused on pediatric oncology applications.
The CCDI's data infrastructure expansion was identified as a critical enabler, as AI model training for cancer research requires large, well-curated datasets; the CCDI's existing collection of multi-omics and clinical data from pediatric cancer patients across children's hospitals represented one of the most valuable such datasets available.
Broader Context: AI and Biomedical ResearchEdit
EO 14355 was part of a pattern of Trump administration executive orders connecting AI to specific health and science missions. The Genesis Mission (November 2025) similarly directed DOE National Laboratories to apply AI to scientific discovery, including in biotechnology. The administration's position was that AI represented a transformational tool for biomedical research, capable of compressing the timeline from discovery to clinical application.[7]